MichBio Joins Letter Urging Changes to Proposed COINS Act Rules
MichBio has joined the INCUBATE Coalition in calling for clearer biotechnology investment rules that protect national security without unnecessarily restricting licensing, financing, and development partnerships. Industry stakeholders can sign the coalition letter by December 1, 2026, at 6 p.m. ET.
MichBio has signed on to an INCUBATE Coalition letter urging Congress and the U.S. Treasury Department to address concerns with the biotechnology provisions of Treasury’s proposed rules implementing the Comprehensive Outbound Investment National Security (COINS) Act. The effort supports strong national security safeguards while seeking to preserve investment and partnerships that bring promising treatments into U.S. development.
INCUBATE is inviting investors, company executives and leaders across the bioscience community to join the letter - and MichBio endorses the request. Its central concern is that overly broad restrictions could disrupt cross-border licensing, co-development and new-company, or “NewCo”, rrangements that support American biotechnology innovation.
What is at stake?
Treasury released its proposed rule on October 22, expanding the framework for restricting certain U.S. investments involving sensitive technologies and countries of concern. The stated purpose is to prevent American capital and associated expertise from advancing foreign adversaries’ military, intelligence and surveillance capabilities. Biotechnology would become an additional covered sector under the proposal.
For life sciences companies, the concern is how broadly those restrictions could reach. The proposed biotechnology categories encompass pharmaceutical development and enabling technologies, raising questions about the treatment of transactions used to acquire, finance and develop new therapies. MichBio previously outlined these concerns in its October 30 policy update.
Transaction structure matters according to a Morgan Lewis analysis. Standalone drug licenses generally fall outside the proposed investment restrictions, but accompanying equity investments, certain financing arrangements and qualifying joint ventures could be covered. A transaction that combines licensing with investment or shared development therefore requires closer consideration.
What the INCUBATE letter seeks
INCUBATE’s sign-on campaign calls on policymakers to:
-
Maintain strong safeguards against genuine national security threats.
-
Preserve cross-border licensing, co-development and NewCo structures that bring new treatments to American patients.
-
Protect the investment those transactions generate for U.S. biotechnology companies.
These priorities are particularly relevant to emerging companies. A startup may rely on licensed science, outside investment and development partners to assemble a viable pipeline. Uncertainty about permissible deal structures could complicate fundraising, delay partnerships or make a promising program harder to advance.
For Michigan’s bioscience community, the practical objective is a clearly defined framework that protects national security and supports the investment, scientific collaboration and company formation needed to sustain domestic innovation.
Add your voice
MichBio encourages members and other bioscience leaders to review INCUBATE’s letter and consider signing on. The coalition’s sign-on deadline is December 1, 2026, at 6 p.m. Eastern.
Review the letter and add your name and explore INCUBATE’s accompanying China, biotechnology and national security one-pager.
Separately, Treasury is accepting public comments on the proposed rule through December 7, 2026. The biotechnology expansion remains proposed, giving companies and investors an opportunity to explain potential consequences and recommend practical changes before the rules are finalized. MichBio plans to submit comments.

